Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prior Traumatic Brain Injury and Alzheimer Disease Blood Biomarkers.

JAMA neurology·2026
Same author

Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinic.

Metabolic brain disease·2026
Same author

Identification of patients receiving amyloid-targeting therapies in observational studies using amyloid PET trajectories: Insights from LEADS.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.

Alzheimer's research & therapy·2026
Same author

Association of cognitive impairment and APOE ε4 with Centiloids in Hispanic and non-Hispanic White cohorts.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Maison Abu Raya1,2, David N Soleimani-Meigooni3,4,5, Ganna Blazhenets4

  • 1Global Brain Health institute- UCSF, San Francisco, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括
此摘要是机器生成的。

在早期发病的阿尔茨海默氏症 (EOAD) 中,粉样蛋白阳性,阳性 (A + T-) PET 概况很少见,可能表明非常早期的疾病阶段与最小的病理. 这个A+T-组的临床进展比A+T+组慢.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经成像是一种神经成像.
  • 阿尔茨海默氏症疾病研究研究
  • 生物标志物发现发现

背景情况:

  • 在临床受损个体中解释粉样蛋白阳性,阴性 (A+T-) PET 档案对于诊断和预后具有挑战性.
  • 早期发病的阿尔茨海默氏症 (EOAD) 存在独特的诊断障碍.

研究的目的:

  • 确定在早期发病的阿尔茨海默病患者队列中A+T-PET概况的频率.
  • 描述具有A+T-概况的个体的临床和神经成像特征.

主要方法:

  • 来自LEADS队列的568名参与者进行了基线粉样蛋白-PET ([18F]florbetaben) 和tau-PET ([18F]flortaucipir) 扫描的分析.
  • 粉样蛋白阳性 (A+) 定义为[18F]florbetaben PET (≥25 Centiloid). 粉样蛋白阳性 (A+) 定义为[18F]florbetaben PET (≥25 Centiloid). 粉样蛋白阳性 (A+) 定义为[18F]florbetaben PET.
  • 通过专家视觉读取和定量SUVR测量来评估Tau-PET状态,并使用Kruskal-Wallis/Fisher精确测试和纵向下降线性混合效应模型 (CDR-SB) 进行A+T和A+T+组之间的比较.

主要成果:

  • 在粉样蛋白阳性 (A+) 认知障碍 (CI) 参与者中,A+T-概况很少 (3-7%) 发生,不管采用了tau-PET评估方法.
  • 与A+T+组相比,A+T-组表现出较轻微的临床损伤,尽管年龄较大,APOE-e4,高胆固醇和吸烟率较高.
  • 从长度上看,A+T-组的临床进展 (CDR-SB增加) 比A+T+组慢,基线粉样蛋白负担较低,海马体积较大.

结论:

  • 在患有EOAD的A+患者中,tau-PET阳性非常普遍 (93-97%),无论使用何种定义.
  • 在EOAD中罕见的A+T-形状可能代表了早期疾病阶段,其中tau病理处于PET成像检测门以下.
  • 这表明,EOAD中的A+T-概况可能是暂时的状态或暗示了其他潜在病理.